ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

Upton Heads NIH Effort To Define Prevention

April 21, 1978

NCI to Study Review Group’s report Urging Restructure of Prevention Programm

June 27, 1997

As For-Profits Provide Phase I Studies, NCI Seeks to Look Deeper and Learn More

April 6, 2012

Samuels Says Industry Should Pay For Valium Carcinogenicity Tests

March 20, 1981

NCAB Member Seeks Broder’s Resignation, Gets No support

June 3, 1994

DCT Board Approves Lung Cancer Drug Discovery Project, First Targeted Anticancer Agent Search

June 22, 1984